The Phase 1 GALLOP study evaluating the investigational CAR-T therapy, CB-010, for treatment of lupus nephritis has launched.

Myasthenia gravis, which weakens the skeletal muscles, is perhaps the best-known rare autoantibody disease. Maternal-fetal diseases include hemolytic disease of the fetus and newborn (HDFN), in ...

IgG MoDE Degraders: BHV-1300 Phase 1 completing last remaining dose cohorts with the optimized subcutaneous formulation with expected completion in 1H 2025. BHV-1310 first-in-human study anticipated ...

Unfortunately, the diagnostic and prognostic use of thyroid autoantibody measurements is hampered by technical problems as discussed below. Although autoantibody tests have inherent clinical ...

The major study objective was to assess the efficacy of autoantibody testing to predict the risk of CAM. The “antibody-negative” result on “routine” antibody testing demonstrates very high sensitivity ...

The U.S. Food and Drug Administration (FDA) has granted Priority Review to Johnson & Johnson’s Biologics License Application ...

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...

House: Johnson & Johnson has announced the nipocalimab Biologics License Application (BLA) has received Priority Review ...

In a report released today, Sami Corwin from William Blair maintained a Buy rating on Cabaletta Bio (CABA – Research Report). The company’s ...

FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...